Pharma

Your Article Summary

See Latest Articles

New Study in Women with Fabry Disease, Demonstrates Significant Benefits of Treatment with REPLAGAL (agalsidase alfa) 0.2mg/kg on Kidney Function, Heart Function and Burden of Disease
Shire, 06/17/09

Authors concluded that this observational study, which included 36 women and lasted for 4 years, indicates that women with signs and symptoms of Fabry disease should be considered for ERT with agalsidase alfa, noting that the patient population studied may not be representative of the general Fabry disease female population.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

CCHIT Appoints Officers
HealthDataManagement, 12/18/09

 See all of Research & Development